Ultima

What Ultima does

Ultima is presented in the aggregated data as a genomics technology company focused on sequencing instrumentation and omics analysis. The company's primary known product is the UG 200 series, which was announced at the AGBT (Advances in Genome Biology and Technology) conference in Orlando in February 2026. The platform is described as employing a novel method architecture and is positioned by the source as competing in the genomics sequencing market alongside established players such as Illumina and Stellaromics. The stated end-market is genomics researchers, laboratories, and institutions conducting genomic research, sequencing, and multiomics analysis, with horizontal segmentation across these use cases.

The evidence base for the company is extremely thin. No financials, funding history, headcount, ownership, management, or commercial traction data are available. The aggregated dataset also contains material entity-resolution conflicts: one firmographic block describes Ultima as a 2021-founded online education company (ultima.school, 11–50 employees, Delaware City, US), while the remainder of the evidence describes a genomics instrumentation company; these two profiles are not internally consistent. Additionally, a large block of scraped Vietnamese-language content about football betting odds was included in the data set but is unrelated to either Ultima profile and has been excluded. Accordingly, this description is constrained to what the single source-backed product/technology thread supports, and the conflicting firmographic profile is not asserted as fact.

Name

Ultima

Website

https://ultima.school

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Ultima is a genomics sequencing technology company that announced its UG 200 series sequencing platform at the AGBT conference in Orlando, targeting genomics researchers, laboratories, and institutions conducting sequencing and multiomics work.

Ownership category

akta.pro rank

Product category

Genomics Sequencing Instruments

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Genomics sequencing
• DNA sequencing instruments
• Multiomics analysis
• Omics research platforms
• Sequencing technology

Headquarters

HQ city

Delaware City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Core offering

Ultima develops and sells genomics sequencing instruments and platforms used for omics research and analysis. Its flagship product, the UG 200 series, was unveiled at the AGBT conference and targets genomics research, genomic sequencing, and multiomics analysis workflows for laboratories and research institutions.

Product overview

Ultima appears to be a genomics technology company that offers products for omics research and analysis. Based on the available information, the company has launched its UG 200 series product at a major genomics conference (AGBT). The product portfolio appears to include genomics instruments/platforms, though detailed information about additional products or modules is not available from the current sources.

Differentiator

Problem solved

Functional benefit

Brands

• UG 200 series: Product launch announced at AGBT conference

Products and services

• UG 200 series

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Expansion highlights2 records

Emerging players

• Stellaromics: Spatial omics platform company explicitly named alongside Ultima at the AGBT launch. Comparable as a recent entrant with a novel technology architecture targeting multiomics-adjacent research customers.
• Standard BioTools (formerly Fluidigm): Provider of mass cytometry and genomics instrumentation (Biomark) for multiomics research applications. Comparable as a smaller-cap research-instrument peer with a similar customer profile in translational and multiomics labs.
• 10x Genomics: Provider of single-cell and spatial genomics tools (Chromium, Xenium, Visium) widely used in multiomics research. Comparable in serving the same multiomics research customer base that Ultima's UG 200 series targets.

Direct peers

• Singular Genomics: Maker of the G4 benchtop sequencer positioned at research and translational genomics customers. Comparable as a small-cap NGS instrument peer with a novel architecture competing for the same horizontal research segment.
• Oxford Nanopore Technologies: Provider of nanopore-based sequencing (PromethION, GridION, MinION) used in genomics and multiomics research. Comparable as an NGS platform peer with a differentiated method architecture targeting the same research customer base.
• Pacific Biosciences: Long-read sequencing platform (Revio, Sequel II) serving genomics researchers and multiomics applications. Comparable in offering sequencing instruments to research labs and competing for the same multiomics-driven workflows.
• Element Biosciences: Developer of the AVITI benchtop sequencing platform, a direct NGS instrument competitor to Ultima's UG 200 series. Comparable in targeting genomics research labs with a novel sequencing chemistry and lower-cost positioning versus Illumina.
• MGI Tech (BGI Group): Global NGS instrument and reagent provider (DNBSEQ platforms) competing on cost-performance in research sequencing. Comparable as a direct NGS platform rival pursuing price-disruptive positioning.

Broad incumbents

• Illumina: Dominant short-read sequencing platform provider (NovaSeq, NextSeq, MiSeq) and the de facto standard against which Ultima explicitly positions itself. Comparable because Ultima's UG 200 series is described as competing in the same NGS research workflow.
• QIAGEN: Broad life-science tools provider with sample-prep, NGS library, and bioinformatics offerings used by genomics research labs. Comparable as a broader incumbent serving the same genomics research workflow that UG 200 plugs into.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ultima